TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months

Severe tricuspid regurgitation (TR) is associated with high mortality and morbidity. For patients with high surgical risk that cannot get surgery, the endovascular option has become an attractive solution this past decade.  Transcatheter intervention has focused on edge-to-edge repair and valve replacement. However, their success depends on anatomical characteristics and imaging guidance effectiveness.  The bicaval<a href="https://solaci.org/en/2022/07/15/tricvalve-in-patients-with-severe-tricuspid-regurgitation-promising-results-at-6-months/" title="Read more" >...</a>

Post-MitraClip Mitral Valve Stenosis: Bad Prognosis

The EVEREST II trial has shown the MitraClip has similar mortality rate to that of surgery and, on the other hand, we are well aware that residual mitral regurgitation (MR) is associated with a strong negative impact. However, research has shown little about transvalvular gradient after MitraClip and what it entails. 268 patients receiving MitraClip were<a href="https://solaci.org/en/2022/06/03/post-mitraclip-mitral-valve-stenosis-bad-prognosis/" title="Read more" >...</a>

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Real World Outcomes on Edge-to-Edge Tricuspid Valve Repair: 30 Day Outcomes of the TriClip bRight

This study was carried out to assess the safety and efficacy of the TriClip (edge-to-edge repair) in patients with severe tricuspid regurgitation with persistent symptoms despite medical treatment and high surgical risk.  It is a prospective multicenter single arm study including 300 patients of mean age 78±7.6; 7.7% presented prior aortic intervention and 28% prior<a href="https://solaci.org/en/2022/05/26/europcr-2022-real-world-outcomes-on-edge-to-edge-tricuspid-valve-repair-30-day-outcomes-of-the-triclip-bright/" title="Read more" >...</a>

EuroPCR 2022 | 1 Year Outcomes of Tricuspid Valve Repair with Cardioband: Feasibility Study

Tricuspid failure is a prevalent valvulopathy most often mistreated. It has been associated with high surgical risk and medical treatment has showed substandard therapeutic effect. Surgical repair with valve annuloplasty is the technique of choice for its long-term durability. Transcatheter repair of the tricuspid valve is an alternative that aims at imitating annuloplasty by reducing<a href="https://solaci.org/en/2022/05/24/europcr-2022-1-year-outcomes-of-tricuspid-valve-repair-with-cardioband-feasibility-study/" title="Read more" >...</a>

EuroPCR 2022 | Jenavalve Trilogy System: Valve for Severe Aortic Regurgitation

Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they have often been used to treat aortic regurgitation as an off-label indication. The Jenavalve Trilogy valve has recently received the CE Mark for aortic regurgitation and aortic stenosis.  This study included 45 patients with severe AR. Primary end<a href="https://solaci.org/en/2022/05/23/europcr-2022-jenavalve-trilogy-system-valve-for-severe-aortic-regurgitation/" title="Read more" >...</a>

EuroPCR 2022 | Changes in Cardiac Damage after Surgical Aortic Valve Replacement

This study presented at EuroPCR 2022 analyzed the PARTNER study pool and included 1974 patients with a complete echocardiogram. Surgical risk was 17.3% extreme/inoperable, 54.3% intermediate and 28.4% low. 60% received transcatheter aortic valve replacement (TAVR) and the rest surgical aortic valve replacement (SAVR).  6.1% of patients were in stage 0 (no damage), 14.5% were<a href="https://solaci.org/en/2022/05/19/europcr-2022-changes-in-cardiac-damage-after-surgical-aortic-valve-replacement/" title="Read more" >...</a>

Is Increased Mitral Valve Gradient After MitraClip a Long-Term Prognostic Factor?

Transcatheter mitral valve repair using the edge-to-edge strategy has become a therapeutic alternative for patients with severe primary mitral valve regurgitation (MVG) who are at high or extreme surgical risk. However, both degree of residual regurgitation and gradient after the procedure should be taken into account, as in previous studies the latter was associated with<a href="https://solaci.org/en/2022/05/09/is-increased-mitral-valve-gradient-after-mitraclip-a-long-term-prognostic-factor/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

Avatar Trial: Is It Time to Use Surgical Aortic Valve Replacement in Asymptomatic Patients?

It is still unclear whether surgical aortic valve replacement (SAVR) is beneficial in asymptomatic patients with severe aortic stenosis (AS) and conserved left ventricular function (C1 indication according to AHA guidelines). The European American guidelines only recommend intervention in asymptomatic patient when there is ventricular compromise (ejection fraction <50%, class I indication) or with a<a href="https://solaci.org/en/2022/05/05/avatar-trial-is-it-time-to-use-surgical-aortic-valve-replacement-in-asymptomatic-patients/" title="Read more" >...</a>

ACC 2022 | CLASP TR Study: Tricuspid Valve Repair with the PASCAL Device

The study included 65 patients who received endovascular treatment of the tricuspid valve with the PASCAL device. Forty-six completed the 12-month follow-up. At 1-year follow-up, the major events endpoint was 16.9%; the most frequent event was bleeding (9.2%). In addition, there were three cases of stroke, one reintervention, two vascular access complications, and five cardiovascular-related<a href="https://solaci.org/en/2022/04/13/acc-2022-clasp-tr-study-tricuspid-valve-repair-with-the-pascal-device/" title="Read more" >...</a>

Tavi en pacientes com bajo flujo, bajo gradiente clásico

TRICENTO: Promising Results for Severe Tricuspid Valve Regurgitation

Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table.   Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices.  The TRICENTO has an<a href="https://solaci.org/en/2022/03/25/tricento-promising-results-for-severe-tricuspid-valve-regurgitation/" title="Read more" >...</a>